Oppenheimer analyst Jay Olson raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $375.00 (from $320.00) while maintaining a Outperform rating.

Analyst PT Change

Madrigal Pharmaceuticals (MDGL) PT Raised to $405 at Evercore ISI, 'well positioned to execute on the launch of Rezdiffra'March 19, 2024 2:50 PM Citi Closes 30-Day Upside Catalyst Watch on Madrigal Pharmaceuticals (MDGL)March 18, 2024 4:04 PM